The development, content and response process validation of a caregiver-reported severity measure for CDKL5 deficiency disorder
Year: 2023
Type: article
Source: Epilepsy Research
Institutions: Children's Hospital Colorado, University of Colorado Anschutz, University of Colorado Denver, The Kids Research Institute Australia, The University of Western Australia, Children's Hospital of Philadelphia, Baylor College of Medicine, Texas Children's Hospital, Cleveland Clinic, Boston Children's Hospital, NYU Langone Health, New York University, Washington University in St. Louis, University of California, Los Angeles, Mattel Children's Hospital, Curtin University
Language: English
Subfield: Education
Field: Social Sciences
Domain: Social Sciences
Open Access status: green
Funders: International Rett Syndrome Foundation, University of Pennsylvania, Zogenix, Ultragenyx Pharmaceutical, Ionis Pharmaceuticals, GW Pharmaceuticals, ACADIA Pharmaceuticals, Georgia Clinical and Translational Science Alliance, Rett Syndrome Research Trust, Marinus Pharmaceuticals, LouLou Foundation, International Foundation for CDKL5 Research, National Institutes of Health, National Health and Medical Research Council, National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Child disability:understanding determinants and improving outcomes, G1705418431, Diagnosis and genotype-phenotype correlations in early life epilepsy and CDKL5 disorder, G6874477042, Colorado Clinical and Transational Sciences Institute, G9000110373, Multi-Site Validation of Biomarkers and Core Clinical Outcome Measures for Clinical Trials Readiness in CDKL5 Deficiency Disorder, Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center, Colorado Clinical and Translational Sciences Institute (CCTSI)
OpenAlex ID: W4386892992